Imperial College London
Portrait Picture

DrFionaWatt

Faculty of Medicine, Department of Immunology and Inflammation

Reader in Rheumatology
 
 
 
//

Contact

 

f.watt

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Kingsbury:2013:10.1186/1745-6215-14-64,
author = {Kingsbury, SR and Tharmanathan, P and Adamson, J and Arden, NK and Birrell, F and Cockayne, S and Dickson, J and Doherty, M and Dziedzic, KS and Grainger, A and Hewitt, CE and O'Neill, TW and Scott, DL and Vincent, TL and Wakefield, RJ and Watt, FE and Torgerson, DJ and Conaghan, PG},
doi = {10.1186/1745-6215-14-64},
journal = {Trials},
pages = {1--12},
title = {Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis (HERO): study protocol for a randomized controlled trial},
url = {http://dx.doi.org/10.1186/1745-6215-14-64},
volume = {14},
year = {2013}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundOsteoarthritis (OA) is the most common type of arthritis, causing significant joint pain and disability. It is already a major cause of healthcare expenditure and its incidence will further increase with the ageing population. Current treatments for OA have major limitations and new analgesic treatments are needed. Synovitis is prevalent in OA and is associated with pain. Hydroxychloroquine is used in routine practice for treating synovitis in inflammatory arthritides, such as rheumatoid arthritis. We propose that treating patients with symptomatic hand OA with hydroxychloroquine will be a practical and safe treatment to reduce synovitis and pain.Methods/designHERO is an investigator-initiated, multicentre, randomized, double-blind, placebo-controlled trial. A total of 252 subjects with symptomatic hand OA will be recruited across primary and secondary care sites in the UK and randomized on a 1:1 basis to active treatment or placebo for 12 months. Daily medication dose will range from 200 to 400 mg according to ideal body weight. The primary endpoint is change in average hand pain during the previous two weeks (measured on a numerical rating scale (NRS)) between baseline and six months. Secondary endpoints include other self-reported pain, function and quality-of-life measures and radiographic structural change at 12 months. A health economics analysis will also be performed. An ultrasound substudy will be conducted to examine baseline levels of synovitis. Linear and logistic regression will be used to compare changes between groups using univariable and multivariable modelling analyses. All analyses will be conducted on an intention-to-treat basis.DiscussionThe HERO trial is designed to examine whether hydroxychloroquine is an effective analgesic treatment for OA and whether it provides any long-term structural benefit. The ultrasound substudy will address whether baseline synovitis is a predictor of therapeutic response. This will potentially provide a n
AU  - Kingsbury,SR
AU  - Tharmanathan,P
AU  - Adamson,J
AU  - Arden,NK
AU  - Birrell,F
AU  - Cockayne,S
AU  - Dickson,J
AU  - Doherty,M
AU  - Dziedzic,KS
AU  - Grainger,A
AU  - Hewitt,CE
AU  - O'Neill,TW
AU  - Scott,DL
AU  - Vincent,TL
AU  - Wakefield,RJ
AU  - Watt,FE
AU  - Torgerson,DJ
AU  - Conaghan,PG
DO  - 10.1186/1745-6215-14-64
EP  - 12
PY  - 2013///
SN  - 1745-6215
SP  - 1
TI  - Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis (HERO): study protocol for a randomized controlled trial
T2  - Trials
UR  - http://dx.doi.org/10.1186/1745-6215-14-64
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000321926400001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR  - https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-14-64
UR  - http://hdl.handle.net/10044/1/101591
VL  - 14
ER  -
Download